Interleukin-2 after autologous stem cell transplantation for hematologic malignancy: A phase I/II study

Abstract

The success of autologous stem cell transplantation (ASCT) for hematologic malignancy is limited largely by a high relapse rate, It is postulated that IL-2 administered after ASCT may eliminate minimal residual disease and thereby reduce relapses, A phase I/II study was performed to identify a regimen of IL-2 (Chiron) that could be given early after ASCT in phase III trials. In the phase I study, beginning a median of 46 days after ASCT for for hematologic malignancy, cohorts of three to four patients received escalating doses of 'induction' IL-2 of 9, 10 or 12 x 106 IU/m2/day for 4 or 5 days by continuous i.v. infusion (CIV), followed by a 4-day rest period and then 1.6 x 106 IU/m2/day of maintenance IL-2 by CIV for 10 days. The maximum tolerated dose (MTD) of induction IL-2 was 9 x 106 IU/m2/day x 4. In the phase II study, 52 patients received the MTD. Eighty percent of patients completed induction IL-2. Most patients exhibited some degree of capillary leak. One patient died of CMV pneumonia and one died of ARDS. Maintenance IL-2 was well tolerated. In the phase I/II study, 16 of 31 patients with non-Hodgkin lymphoma (NHL), 3/8 with Hodgkin disease (HD), 4/17 with AML, and 4/5 with ALL remain in CR. Two of six multiple myeloma (MM) patients remain in PR. Although the regimen of IL-2 identified had significant side-effects in some patients, it was well tolerated in the majority of patients. Phase III prospectively randomized clinical trials are in progress to determine if this IL-2 regimen will decrease the relapse rate after ASCT for AML and NHL.